Ovid Therapeutics

Update in progress

OVID (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ovid Therapeutics is a biopharmaceutical company focused on developing small-molecule medicines for brain disorders, including epilepsies and seizure-related conditions in the U.S. It is advancing OV329, a GABA-AT inhibitor in Phase 1 for adult and infant drug-resistant epilepsies, and OV4071, a first-in-human oral KCC2 activator in Phase 1 for psychosis related to Parkinson’s, Lewy body dementia, and acute schizophrenia. Partners include AstraZeneca, Lundbeck, Northwestern, Graviton, and Marinus. Founded 2014; based in New York.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.03; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive